Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / COM
-
Number of holders
-
62
-
Total 13F shares, excl. options
-
11,908,531
-
Shares change
-
+3,716,423
-
Total reported value, excl. options
-
$17,628,861
-
Value change
-
+$1,905,095
-
Put/Call ratio
-
19%
-
Number of buys
-
48
-
Number of sells
-
-33
-
Price
-
$1.48
Significant Holders of Protalix BioTherapeutics, Inc. - COM (PLX) as of Q2 2025
98 filings reported holding PLX - Protalix BioTherapeutics, Inc. - COM as of Q2 2025.
Protalix BioTherapeutics, Inc. - COM (PLX) has 62 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 11,908,531 shares
.
Largest 10 shareholders include BlackRock, Inc. (3,369,670 shares), RENAISSANCE TECHNOLOGIES LLC (1,615,003 shares), NORTHERN TRUST CORP (1,079,723 shares), GEODE CAPITAL MANAGEMENT, LLC (826,333 shares), Connor, Clark & Lunn Investment Management Ltd. (496,216 shares), VANGUARD GROUP INC (484,798 shares), MORGAN STANLEY (462,043 shares), STATE STREET CORP (444,239 shares), Stratos Wealth Partners, LTD. (350,000 shares), and SUSQUEHANNA INTERNATIONAL GROUP, LLP (298,567 shares).
This table shows the top 62 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.